{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"Refining Goals in the Pharmacological Control of Attention Deficit Hyperactivity Disorder - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"26KItoHlm5\"><a href=\"https:\/\/themedicalxchange.com\/en\/2012\/05\/22\/165th-american-psychiatric-association-apa-annua-2\/\">Refining Goals in the Pharmacological Control of Attention Deficit Hyperactivity Disorder<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/2012\/05\/22\/165th-american-psychiatric-association-apa-annua-2\/embed\/#?secret=26KItoHlm5\" width=\"600\" height=\"338\" title=\"&#8220;Refining Goals in the Pharmacological Control of Attention Deficit Hyperactivity Disorder&#8221; &#8212; The Medical Xchange\" data-secret=\"26KItoHlm5\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/05\/APA_2327_EN_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Philadelphia \u2013 Progress is being made in defining the next step in the control of attention deficit hyperactivity disorder (ADHD) when standard regimens fail or are inadequate. At the 2012 American Psychiatric Association (APA) Annual Meeting, positive results have been reported with both a novel therapy and a new delivery system designed to improve control in suboptimal treatment of ADHD. The alternatives are filling a large gap that is now largely bridged by empiric use of unproven psychoactive therapies, particularly atypical antipsychotics. The considerable potential risks of atypical antipsychotics have increased demand for alternatives. The current effort to improve control of ADHD refractory to first-line psychostimulants has major implications for a more rational approach to a disorder which now affects nearly 10% of school-aged children."}